Multimodal treatment of thymic carcinoid: a case report

Vnitr Lek. 2019 Spring;65(5):363-368.

Abstract

Thymic carcinoid account for cca 0.4 % of all carcinoid tumors in the body [1]. As compared to other neuroendocrinne tumors, high rates of reccurences after surgery, more aggressive behaviour and relatively high rates of paraneoplastic syndromes are characteristic for thymic carcinoid. The mainstay of treatment is radical surgery [2-4]. Therapy of locally advanced and metastatic stages is influenced by other neuroendocrinne tumors´guidelines. We present a case report of patient with locally advanced, atypical thymic carcinoid, treated with different modalities, including newer procedures like peptide radionuclide receptor therapy (PRRT).

Keywords: peptide radionuclide receptor therapy; somatostatine analogues; thymic carcinoid.

Publication types

  • Case Reports

MeSH terms

  • Carcinoid Tumor* / therapy
  • Combined Modality Therapy
  • Humans
  • Thymus Neoplasms* / therapy